Search
MK-0777
go.drugbank.com/drugs/DB12238InvestigationalMK-0777 has been used in trials studying the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPolatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigationalconsists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesBenzbromarone
go.drugbank.com/drugs/DB12319ApprovedWithdrawnBenzbromarone has been used in trials studying the basic science and treatment of Heart Failure, Hyperuricemia, Chronic Kidney Disease, Abnormal Renal Function, and Gout and Asymptomatic Hyperuricemia.
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsBetrixaban
go.drugbank.com/drugs/DB12364ApprovedBetrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its fa...
Categories: P-glycoprotein substratesSiponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigationalSiponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesIndirubin
go.drugbank.com/drugs/DB12379InvestigationalIndirubin is under investigation in clinical trial NCT01735864 (Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesLisofylline
go.drugbank.com/drugs/DB12406InvestigationalLisofylline has been investigated for the treatment of Type 1 Diabetes Mellitus.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesFavipiravir
go.drugbank.com/drugs/DB12466ApprovedInvestigationalDiscovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzyme...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2C8 InhibitorsIbrexafungerp
go.drugbank.com/drugs/DB12471ApprovedIbrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. It was developed out of...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigationalMirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound D...
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates